**1. Introduction**

440 Cancer Prevention – From Mechanisms to Translational Benefits

[38] Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y. The cost of prostate cancer

[39] Zeliadt SB, Etzioni RD, Penson DF, Thompson IM, Ramsey SD. Lifetime implications

[40] Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y. Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis. Cancer 2008;112:1058-65. [41] Svatek RS, Lotan Y. Cost utility of prostate cancer chemoprevention with dutasteride in

[42] Strope SA, Andriole GL. Update on chemoprevention for prostate cancer. Curr Opin

[43] Crawford ED, Andriole GL, Marberger M, Rittmaster RS. Reduction in the risk of

[44] Berglund RK, Masterson TA, Vora KC, Eggener SE, Eastham JA, Guillonneau BD.

[46] Hamilton RJ, Kahwati LC, Kinsinger LS. Knowledge and use of finasteride for the prevention of prostate cancer. Cancer Epidemiol Biomarkers Prev;19:2164-71. [47] Andriole G, Bostwick D, Brawley O, et al. Chemoprevention of prostate cancer in men

eligible for active surveillance. J Urol 2008;180:1964-7; discussion 7-8. [45] Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary

of the American Society of Clinical Oncology 2010;28:1117-23.

events (REDUCE) trial. J Urol 2004;172:1314-7.

2006;15:1485-9.

2005;118:850-7.

Urol;20:194-7.

Urology;75:502-9.

83.

chemoprevention: a decision analysis model. Cancer Epidemiol Biomarkers Prev

and cost-effectiveness of using finasteride to prevent prostate cancer. Am J Med

men with an elevated prostate specific antigen. Cancer Prev Res (Phila) 2011;4:277-

prostate cancer: future directions after the Prostate Cancer Prevention Trial.

Pathological upgrading and up staging with immediate repeat biopsy in patients

treatment of localized prostate cancer. Journal of clinical oncology : official journal

at high risk: rationale and design of the reduction by dutasteride of prostate cancer

Endometrial cancer is the most common gynecological cancer in developed countries. Endometrial cancer primarily affects postmenopausal women, with a median age at diagnosis of 60 years approximately 25% of women are premenopausal at diagnosis and up to 5% of these are below the age of 40 years [Orr, 1997].
